Read This Before Anything Else on the Page

The American Society of Regional Anesthesia consensus guidelines on ketamine for chronic pain describe intravenous infusion protocols with continuous monitoring, at dose ranges a sublingual home program does not reach. Sites that cite those guidelines to sell at-home ketamine for pain are borrowing credibility from a route they are not using. We would rather lose the patient than blur that. If chronic pain is your main problem, an infusion clinic or a pain specialist is frequently the better referral.

• The consensus guidelines address intravenous ketamine, not sublingual
• Home dosing does not reach infusion-protocol exposure
• Complex regional pain syndrome has the strongest evidence, and it is IV evidence
• We refer out when pain is primary rather than treating at the edge of the data
• Nothing here is a reason to stop a working pain regimen

Where At-Home Ketamine Does Have a Role

The defensible case is the depression that chronic pain produces. Persistent pain and mood disorder maintain each other: pain drives insomnia and inactivity, those deepen depression, and depression lowers pain tolerance. Ketamine has strong evidence in treatment-resistant depression, and treating the mood component can loosen that loop even when it does not directly reduce nociception.

• Depression secondary to chronic pain is a well-supported target
• Improved mood and sleep frequently improve reported pain interference
• Pain interference and pain intensity are different outcomes; we track both
• This is an adjunct to pain management, never a substitute for it
• Your pain physician stays in charge of the pain plan

Central Sensitization, Honestly Described

The mechanistic argument for ketamine in pain is real. NMDA receptors participate in the wind-up phenomenon that underlies central sensitization, where the nervous system amplifies signals out of proportion to tissue damage. Blocking those receptors is a coherent rationale, and it is why fibromyalgia and neuropathic presentations come up. A coherent mechanism is not the same as demonstrated benefit at home doses, and the honest position is that the mechanism is better established than the sublingual outcome data.

• NMDA involvement in wind-up and central sensitization is well described
• Fibromyalgia and neuropathic pain are where the rationale is strongest
• Nociceptive pain from ongoing tissue damage is a poorer fit
• Mechanism supports the hypothesis; it does not substitute for outcome data
• Opioid-tolerant patients are a distinct clinical situation requiring specialist input

Medication Review Matters More Here

Chronic pain patients typically arrive on the most complex medication lists we see, and several of those drugs interact meaningfully with a ketamine course. This review is more involved than for a straightforward depression case and is done drug by drug rather than by category.

• Opioids and ketamine both affect respiration; combinations need care
• Gabapentin and pregabalin are common and generally compatible
• Duloxetine is frequently present and is reviewed for serotonergic load
• Muscle relaxants add sedation and are checked individually
• Benzodiazepines may blunt response and are discussed before starting

Candidacy

The criteria here are deliberately restrictive. Patients whose pain is primary, whose regimen includes high-dose opioids, or who have not been evaluated by a pain specialist are usually referred rather than accepted.

• Adults 18 and over with chronic pain and a diagnosed co-occurring mood disorder
• Under the care of a physician managing the pain condition itself
• At least one adequate antidepressant trial for the mood component
• Blood pressure controlled, since ketamine raises it transiently
• No active substance use disorder; opioid-tolerant patients need specialist input
• A sober support person present for every session